Therapeutic Vaccination in Treated HIV Disease

NCT03606213 | Completed Phase 1 Results DMC FDA Drug

• 2 other identifiers: DAIDS-ES 38409U01AI131296
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 2

Brief Summary

The central premise of our program is that durable control of HIV in the absence of antiretroviral therapy ("remission") will require the generation of de novo potent and sustained HIV-specific CD8+ cell responses that target evolutionarily conserved epitopes. Our program is inspired by the recent success of VGX-3100 (Inovio), a DNA therapeutic vaccine for HPV that leads to histopathologic regression of pre-malignant lesions in people and is associated with a potent, sustained boost to HPV-specific CD8+ T cell populations. A closely related multi-clade gag/pol/env DNA vaccine administered with an IL-12 DNA plasmid (PENNVAX, Inovio) has been studied for HIV prevention and is known to be both safe and highly immunogenic. In a randomized placebo-controlled study we will compare the immunogenicity and anti-reservoir activities of gag/pol DNA versus gag/pol/env DNA (both administered with IL-12). We will determine for the first time in established HIV disease whether presence of env in a DNA vaccine blunts T cell responses to more conserved Gag-specific and Pol-specific epitopes. We will also determine if Env-specific responses (which will presumably be mediated by antibodies and antibody-dependent cellular cytotoxicity, or ADCC) have a measurable effect on reservoir.

Conditions

HIV-1-infection

Keywords

HIV Vaccine; Electroporation

Outcome Measures

Primary Outcomes (2)

• The Percentage of Participants With Grade 3 or Higher Treatment-related Adverse Events

  Counts and percentages of adverse events will be presented in frequency tables and characterized for each arm with 95% Clopper-Pearson Confidence Intervals. We will use the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1

  Week 64

• The Change in the Magnitude of T Cell Responses Will be Evaluated by the IFN-γ Enzyme-linked Immunospot (ELISpot) Assay

  The magnitude of Gag-specific responses was characterized in detail via matrix mapping using vaccine-matched peptides, while pools of 15 overlapping peptides will used to evaluate the magnitude of T cell response to Pol and Env, as well as Nef (internal control). In addition, ELISpot responses to pools of Gag, Pol, Env, and Nef peptides (n=50 peptides/pool) that have been derived from circulating HIV viruses (potential T cell epitope peptides, PTE; NIH AIDS Reagent Program) were evaluated in parallel. All measures were performed on two baseline PBMC samples. The primary outcome in terms of the magnitude of the response was calculated as the fold-change (ratio) in the number of spot-forming units per million peripheral blood mononuclear cells between week 14 and baseline (pre-vaccine).

  Baseline to Week 14

Secondary Outcomes (1)

• HIV Reservoir Size

  Baseline and Week 64

Study Arms (4)

Cohort A - Arm 1

PLACEBO COMPARATOR

Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12

Device: CELLECTRA® 2000

Cohort A - Arm 2

ACTIVE COMPARATOR

Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.

Biological: PENNVAX-GP; Biological: INO-9012; Device: CELLECTRA® 2000

Cohort A - Arm 3

ACTIVE COMPARATOR

Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.

Biological: INO-6145; Biological: INO-9012; Device: CELLECTRA® 2000

Cohort B - Arm 1

ACTIVE COMPARATOR

A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.

Biological: PENNVAX-GP; Biological: INO-9012; Device: CELLECTRA® 2000

Interventions

PENNVAX-GP BIOLOGICAL

PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.

Also known as: HIV DNA vaccine

Cohort A - Arm 2; Cohort B - Arm 1

INO-6145 BIOLOGICAL

INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.

Also known as: HIV DNA vaccine

Cohort A - Arm 3

INO-9012 BIOLOGICAL

The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.

Also known as: IL-12 DNA adjuvant

Cohort A - Arm 2; Cohort A - Arm 3; Cohort B - Arm 1

CELLECTRA® 2000 DEVICE

Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.

Also known as: Electroporation device

Cohort A - Arm 1; Cohort A - Arm 2; Cohort A - Arm 3; Cohort B - Arm 1

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing and able to provide written informed consent
• Male or female, age ≥ 18 and ≤ 65 years
• HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load.
• For Cohort A participants, ART initiated during chronic infection (e.g., more than 6 months after estimated date of infection, or as determined by site investigator and/or available medical records).
• For Cohort B participants, ART initiated during "hyperacute" HIV infection (Fiebig I/II) or early HIV infection (Fiebig III/IV).
• On continuous antiretroviral therapy for at least 24 months without any interruptions of greater than 14 consecutive days, and on a stable regimen for at least 8 weeks, without plans to modify ART during the study period
• Screening plasma HIV RNA levels \< 40 copies/mL on all available determinations in past 24 months (isolated single values ≥ 40 but \< 200 copies/mL will be allowed if they were preceded and followed by undetectable viral load determinations)
• Screening CD4+ T-cell count ≥ 350 cells/mm3
• Creatinine Clearance (CrCl) \> 60 mL/min via Cockroft-Gault method at screening
• The following laboratory criteria must be met at screening:
• Absolute neutrophil count (ANC) ≥ 1000 neutrophils/mm3
• Hemoglobin ≥ 10.0 g/dL
• Platelet count ≥ 100,000/uL
• Aspartate aminotransferase (AST) ≤ 2x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) ≤ 2x ULN

You may not qualify if:

• \. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
• a. Acceptable birth control is defined as the following: i. For female participants of childbearing potential, two of the following forms of contraception are required, one of which must be a barrier method:
• \. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent.
• \. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements or to give informed consent.
• \. Unable to undergo leukapheresis procedure 10. Acute or chronic bleeding or clotting disorder that would contraindicate IM injections or use of blood thinners (e.g. anticoagulants or antiplatelet drugs) within 2 weeks of Day 0; 11. Less than two acceptable sites available for IM injection considering the deltoid and anterolateral quadriceps muscles; 12. Tattoos, keloids or hypertrophic scars located within 2 cm of intended treatment site; 13. Cardioverter-defibrillator or pacemaker (to prevent a life-threatening arrhythmia) that is located in ipsilateral deltoid injection site (unless deemed acceptable by a cardiologist); 14. Metal implants or implantable medical device within the intended treatment site (i.e. electroporation area)

Sponsors & Collaborators

• Steven Deeks: lead
• National Institute of Allergy and Infectious Diseases (NIAID): collaborator
• University of California, Los Angeles: collaborator
• Inovio Pharmaceuticals: collaborator

Study Sites (2)

University of California, Los Angeles

Los Angeles, California, 90025, United States

Location

Zuckerberg San Francisco General Hospital (ZSFG)

San Francisco, California, 94110, United States

Location

MeSH Terms

Interventions

rocakinogene sifuplasmid

Results Point of Contact

• Title: Professor of Medicine
• Organization: University of California, San Francisco (UCSF)

Steven.Deeks@ucsf.edu

14154761000

Study Officials

• Steven Deeks, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 2, 2018
• First Posted: July 30, 2018
• Study Start: August 1, 2018
• Primary Completion: May 17, 2021
• Study Completion: May 17, 2021
• Last Updated: May 31, 2023
• Results First Posted: May 31, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)